metabolic research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-06. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== Prognosis == Long-term outcomes for people with sCSFLS remain poorly studied. Symptoms may resolve in as little as two weeks as the dura mater lining heals naturally, or they can persist for months. Less commonly, patients may have unremitting symptoms for many years. People with chronic sCSFLS may be disabled and unable to work. Recurrent CSF leak at an alternate site after recent repair is common.
== Ownership == The British pharmaceutical firm Beecham was the longtime owner of Brylcreem. Sara Lee acquired the personal care unit of SmithKline Beecham in June 1993. In January 2012, the global rights to the Brylcreem brand were sold by Sara Lee Corporation to Unilever. Brylcreem is marketed in the United States by Combe Incorporated, in Europe by Unilever and in India by Hindustan Unilever Limited. Before Godrej acquired a 51% stake of Sara Lee, in their joint venture Godrej Sara Lee in May 2010, the brand was distributed by Godrej in India.
Also, during the 1981 tour, veteran session drummer Andy Newmark stepped in briefly for Knudsen, who was then in rehab. And by the end of 1981, even Simmons had left the band. Now with no remaining original members and a "leader" in McDonald who was ready for a solo career, the group elected instead to disband after a rehearsal without Simmons, according to an interview with McDonald for Listen to the Music, the Doobie Brothers' official video history/documentary released in 1989. He went on to say that by that point they could not have gotten further away from the Doobies sound if they had tried. Simmons, already at work on his first solo album, Arcade, rejoined for a 1982 farewell tour on the condition that this truly would be the end of the Doobie Brothers. At their last concert at the Greek Theatre in Berkeley, California, on September 11, 1982, they were joined onstage by founding member Tom Johnston for what was presumed to be the final rendition of his staple, "China Grove". Former members Porter, Hossack and Hartman subsequently took the stage for an extended version of "Listen to the Music". Knudsen sang lead vocals while Johnston, Simmons and McFee traded licks on guitar. The live album Farewell Tour was released in 1983 and the Greek Theatre concert was released in 2011 as Live at the Greek Theatre 1982.
The functionality of a given protein is heavily dependent on its structure. Proteins reach this structure through the process of protein folding, which is facilitated by a variety of intra- and inter-molecular bonds. While much of the folding is driven by the formation of hydrogen bonds, covalent bonding of cysteine residues into disulfide bridges imposes constraints that stabilize particular conformations while preventing others from forming. As the bond energy of a covalent disulfide bridge is higher than the energy of a coordinate bond or hydrophobic interaction, greater numbers of disulfide bridges lead to higher energies required for protein denaturation. Disulfide bonds often serve to stabilize protein structures in the more oxidizing conditions of the extracellular environment. Within the cytoplasm, disulfide bonds may instead be reduced (i.e. in -SH form) to their constituent cysteine residues by thioredoxins. Many important cellular enzymes use prosthetic groups ending with sulfhydryl (-SH) moieties to handle reactions involving acyl-containing biochemicals: two common examples from basic metabolism are coenzyme A and alpha-lipoic acid. Cysteine-related metabolites homocysteine and taurine are other sulfur-containing amino acids that are similar in structure, but not coded by DNA, and are not part of the primary structure of proteins, take part in various locations of mammalian physiology. Two of the 13 classical vitamins, biotin and thiamine, contain sulfur, and serve as cofactors to several enzymes.
Sources: en.wikipedia.org
There have been movements to achieve reparations for those formerly held as slaves or for their descendants. Claims for reparations for being held in slavery are handled as a civil law matter in almost every country. This is often decried as a serious problem, since former slaves' relatives lack of money means they often have limited access to a potentially expensive and futile legal process. Mandatory systems of fines and reparations paid to an as yet undetermined group of claimants from fines, paid by unspecified parties, and collected by authorities have been proposed by advocates to alleviate this "civil court problem." Since in almost all cases there are no living ex-slaves or living ex-slave owners these movements have gained little traction. In nearly all cases the judicial system has ruled that the statute of limitations on these possible claims has long since expired. In June 2023, The Brattle Group presented a report at an event at the University of the West Indies in which reparations were estimated, for harms both during and after the period of transatlantic chattel slavery, at over 100 trillion dollars.
== Foods == There were also several types of edible clay, like pasa, which was used as sauce for potatoes and other tubers, and chaco, something used by the poor or religiously devout. As in the rest of Central and South America, chili peppers were an important and highly praised part of their diet.
In 2009, Lilly pleaded guilty for illegally marketing antipsychotic medication Zyprexa and agreed to pay a $1.415 billion penalty that included a criminal fine of $515 million, the largest ever in a healthcare case and the largest criminal fine for an individual corporation ever imposed in a US criminal prosecution of any kind at the time. Eli Lilly has faced many lawsuits from people who claimed they developed diabetes or other diseases after taking olanzapine (branded Zyprexa), an antipsychotic medication, as well as by various governmental entities, insurance companies, and others. Internal documents provided to The New York Times revealed that Lilly had downplayed the risks of Zyprexa. According to the documents, 16 percent of people taking Zyprexa gained more than 66 pounds in their first year, a much larger figure than Eli Lilly had shared with doctors. In 2006, Lilly paid $700 million to settle around 8,000 of these lawsuits, and in early 2007, Lilly settled around 18,000 suits for $500 million, which brought the total Lilly had paid to settle suits related to the drug to $1.2 billion. In March 2008, Lilly settled a suit with the state of Alaska, and in October 2008, Lilly agreed to pay $62 million to 32 states and the District of Columbia to settle suits brought under state consumer protection laws. In 2009, four sales representatives for Eli Lilly filed separate qui tam lawsuits against the company for illegally marketing Zyprexa for uses not approved by the Food and Drug Administration.
=== Bone regeneration === EGF plays an enhancer role on the osteogenic differentiation of dental pulp stem cells (DPSCs) because it is capable of increasing extracellular matrix mineralization. A low concentration of EGF (10 ng/ml) is sufficient to induce morphological and phenotypic changes. These data suggests that DPSCs in combination with EGF could be an effective stem cell-based therapy to bone tissue engineering applications in periodontics and oral implantology.
== Appearance and properties == Emulsions contain both a dispersed and a continuous phase, with the boundary between the phases called the "interface". Emulsions tend to have a cloudy appearance because the many phase interfaces scatter light as it passes through the emulsion. Emulsions appear white when all light is scattered equally. If the emulsion is dilute enough, higher-frequency (shorter-wavelength) light will be scattered more, and the emulsion will appear bluer – this is called the "Tyndall effect". If the emulsion is concentrated enough, the color will be distorted toward comparatively longer wavelengths, and will appear more yellow. This phenomenon is easily observable when comparing skimmed milk, which contains little fat, to cream, which contains a much higher concentration of milk fat. Two special classes of emulsions – microemulsions and nanoemulsions, with droplet sizes below 100 nm – appear translucent. This property is due to the fact that light waves are scattered by the droplets only if their sizes exceed about one-quarter of the wavelength of the incident light. Since the visible spectrum of light is composed of wavelengths between 390 and 750 nanometers (nm), if the droplet sizes in the emulsion are below about 100 nm, the light can penetrate through the emulsion without being scattered. Due to their similarity in appearance, translucent nanoemulsions and microemulsions are frequently confused.
Sources: en.wikipedia.org
Re2O7 + 17 CO → Re2(CO)10 + 7 CO2 If metal oxides are used carbon dioxide is formed as a reaction product. In the reduction of metal chlorides with carbon monoxide phosgene is formed, as in the preparation of osmium carbonyl chloride from the chloride salts. Carbon monoxide is also suitable for the reduction of sulfides, where carbonyl sulfide is the byproduct.
small/non-small cell lung cancer oesophageal cancer uterine cervical cancer urothelial cancer testicular cancer ovarian cancer prostate cancer head and neck cancer Nedaplatin is most often compared to other platinum-based drugs, most notably cisplatin. Many randomized controlled trials have been performed to compare nedaplatin and cisplatin, with uncertain results. One meta-analysis of 14 trials indicated no difference in efficacy in terms of median overall survival. Another meta-analysis of 17 trials looking specifically at concurrent chemoradiotherapy treatment for cervical cancer also found no difference in 3 year all-cause mortality, but did favour nedaplatin for 1 year all-cause mortality.
18 July A survey of more than 3,000 experts finds that the extinction crisis could be worse than previously thought, and estimates that roughly 30% of species "have been globally threatened or driven extinct since the year 1500." The first "dormant" black hole (meaning it does not emit high levels of X-ray radiation) is identified outside the Milky Way. The object, with nine solar masses, orbits a rare O-type star in a system called VFTS 243 within the Large Magellanic Cloud. A study shows that climate change-related exceptional marine heatwaves in the Mediterranean Sea during 2015–2019 resulted in widespread mass sealife die-offs in five consecutive years. 20 July – Scientists report that SARS-CoV-2 builds tunneling nanotubes from nose cells to gain access to the brain. 21 July A potential gene therapy cure for haemophilia B, which corrects the genetic defect associated with the condition is announced with trial results by doctors. It caused a sustained increase in factor IX activity in 9 of 10 patients in the small trial. Sunspot AR3060 explodes early in the morning. It releases a C-5 class solar flare, and a "solar tsunami". The NOAA predicts that a geomagnetic storm from this event will strike the Earth on 23 July, between 0000 UTC and 0400 UTC, as a G2 class storm, with a slight chance of a G3 storm. Aurorae could be visible as far south as 50° N latitude. Researchers report the development of deep learning software that can design proteins that contain prespecified functional sites.
== "Insulin" == "In 1920 the diagnosis of diabetes, particularly in the young and the very young, was essentially a death sentence." "The discovery of insulin represents a real breakthrough that has revolutionized both the therapy and the prognosis of people with diabetes ... Before insulin, diabetes was a dreadful condition associated with bad prognosis and miserable quality of life ... [progressing to] the ineluctable coma-death sequence. In 1889, Joseph von Mering and Oskar Minkowski reported that, in every case, the complete removal of an experimental dog's pancreas produced severe and fatal diabetes. They hypothesized that the consequent diabetic state was "due to loss of an 'internal secretion' of the pancreas rather than [to a loss] of the pancreatic exocrine secretion" (GL.2, p.2). Over the ensuing years, as the endocrine functions of the pancreas (glucagon, insulin, etc.), rather than its exocrine functions (pancreatic juice, etc.), were becoming increasingly better understood, "many investigators [had] endeavoured to obtain some beneficial effect in diabetes mellitus: either by feeding pancreas, or by administration of pancreatic extracts" (FB.2, p.141). The complete chemical structure of insulin was eventually determined by Frederick Sanger and Edward Thompson in 1953 (FS.2; FS.3): and, in 1965 (YW.1; YS.1), the team led by Wang Yinglai (王应睐/王應睞) was not only the first to create synthetic insulin, but was also, in the process, the first to produce a biologically active organic compound from inorganic chemicals.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.